Asthma exacerbation resident survival guide: Difference between revisions
Line 43: | Line 43: | ||
: PaO<sub>2</sub> ≥ 60 mm Hg | : PaO<sub>2</sub> ≥ 60 mm Hg | ||
: PCO<sub>2</sub> < 42 mm Hg </div> | | : PCO<sub>2</sub> < 42 mm Hg </div> | | ||
D03=<div style="float: left; text-align: left; line-height: 150% "> </div> | | D03=<div style="float: left; text-align: left; line-height: 150% ">'''Severe:''' <br> Symptoms: <br> ❑ Breathlessness at rest, sits upright <br> ❑ Speaks words <br> ❑ Usually agitated | ||
D04=<div style="float: left; text-align: left; line-height: 150% "> </div>}} | ---- | ||
Signs: <br> ❑ Tachypnea ≥ 30/min <br> ❑ Using accessory muscles of respiration <br> ❑ Wheezing throughout inhalation and exhalation <br> ❑ Pulse > 120/min <br> ❑ Pulsus paradoxus present | |||
---- | |||
❑ FEV<sub>1</sub> < 40 % <br> | |||
❑ Pulse oximetry < 90 % <br> | |||
❑ ABG: | |||
: PaO<sub>2</sub> < 60 mm Hg | |||
: PCO<sub>2</sub> ≥ 42 mm Hg </div> | | |||
D04=<div style="float: left; text-align: left; line-height: 150% "> '''Imminent respiratory arrest:''' <br> Symptoms: <br> ❑ Drowsy or confused | |||
---- | |||
Signs: <br> ❑ Paradoxical thoracoabdominal movement <br> ❑ Wheeze absent <br> ❑ Bradycardia <br> ❑ Pulsus paradoxus absent due to resp. fatigue | |||
---- | |||
❑ FEV<sub>1</sub> < 25 % <br> | |||
</div>}} | |||
{{familytree/end}} | {{familytree/end}} | ||
Revision as of 20:37, 13 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
- Viral infections
- Exposure to allergen
- Environmental pollutants
- Occupational irritants and sensitizers
- Medications:aspirin
Management
Diagnosis
Characterize the symptoms: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Examine the patient:
)❑ O2 saturation (pulse oximetry) ❑ Spirometry Arterial blood gas (ABG) (PaO2/PCO2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Classify the severity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mild: Symptoms: ❑ Breathlessness while walking ❑ Speaks full sentences Signs: ❑ FEV1 ≥ 70% | Moderate: Symptoms: ❑ Breathlessness at rest, prefers sitting ❑ Speaks phrases ❑ Usually agitated Signs: ❑ FEV1 40-69 %
| Severe: Symptoms: ❑ Breathlessness at rest, sits upright ❑ Speaks words ❑ Usually agitated Signs: ❑ FEV1 < 40 %
| Imminent respiratory arrest: Symptoms: ❑ Drowsy or confused Signs: ❑ FEV1 < 25 % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Management
Moderate exacerbation FEV1/PEF 40-60% Dyspnea with daily activities | Severe exacerbation FEV1/PEF<40% Dyspnea at rest | Respiratory arrest Intubation & mechanical ventilation 100%O2 SABA & Ipratropium IV corticosteroids | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
O2(target>90%sat) Inhaled SABA every 60mins PO corticosteroids | O2(>90%sat) SABA+Ipratropium continuous PO corticosteroids consider adjunct therapy | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Good response FEV1/PEF>70% No distress Stable after 60 mins of Rx Normal H&P | Incomplete response FEV1/PEF 40-60% Mild-mod symptoms | Poor response FEV1/PEF<40% PCO2≥42 mm Hg Confusion and severe symptoms | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discharge | Admit to ward | Admit to ICU | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intubation &ventilation IV Corticosteroids SABA[1] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
- SABA:short acting beta agonist
- FEV1:forced expiratory volume for the for the first second
- PEF: Expiratory peak flow
Do's
- In severe exacerbation unresponsive to initial management, consider using IV Mg sulfate
Don'ts
Not recommended medications during hospitalization or emergency care settings
- Methylxanthine
- Antibiotics(except for comorbid conditions)
- Excessive hydration
- Mucolytics
- Chest physical therapy
- Sedation
References
- ↑ National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda (MD): National Heart, Lung, and Blood Institute (US); 2007 Aug. Section 5, Managing Exacerbations of Asthma.Available from: http://www.ncbi.nlm.nih.gov/books/NBK7228/